---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-26-000013"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:53:18.939395+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine Q4 2025 net loss $5.6M; EDIT-401 IND on track mid-2026

## Summary
- Cash $146.6M at Dec 31, 2025, down from $269.9M; runway into Q3 2027.
- Net loss Q4 2025 $5.6M ($0.06/sh) vs $45.4M ($0.55/sh) in Q4 2024.
- Full year 2025 net loss $160.1M ($1.80/sh) vs $237.1M ($2.88/sh) in 2024.
- Lead candidate EDIT-401 achieved >90% mean LDL-C reduction in preclinical; IND/CTA submission expected by mid-2026.
- First-in-human trial in HeFH planned for 2026; early proof-of-concept data targeted by year-end 2026.

## SEC filing metadata
- accession: 0001650664-26-000013
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000013/0001650664-26-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000013/edit-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-26-000013
- JSON: https://secwatch.observer/filing/0001650664-26-000013.json
- Plain text: https://secwatch.observer/filing/0001650664-26-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.